Private Equity’s Rapid Advance Through Healthcare Markets Raises Antitrust Alarm
Private equity has become a powerful force in healthcare, and the trajectory is no longer subtle. A white paper from the American Antitrust Institute and the University of California, Berkeley says investment in the sector has climbed to nearly $750 billion over the last decade, with a business model built around short-term revenue generation, consolidation, and rapid financial return rather than patient welfare.
The central concern is not simply the scale of capital flowing into hospitals, physician practices, and other healthcare assets. It is the way that capital is used. The paper argues that private equity functions as an anticompetitive catalyst, accelerating concentration in already fragile markets and eroding the competitive structure that is supposed to keep prices, access, and quality under pressure from rival providers.
One sentence captures the urgency of the argument plainly: private equity is now moving faster than the regulatory systems built to monitor it.
Growth in Deal Volume Outpaced Oversight
The white paper describes private equity expansion in healthcare as dramatic and likely to continue rising, especially after the COVID-19 pandemic disrupted the sector and altered its growth outlook. The paper does not frame this as a neutral capital trend. Instead, it presents a structural problem: when ownership changes are driven by short-term profit targets, the result can be consolidation that strips away independent decision-making and narrows competition.
That concern extends beyond balance sheets. In healthcare, concentration affects whether patients can choose among clinicians, whether employers and insurers can negotiate with multiple providers, and whether local markets retain enough redundancy to absorb shocks. When private equity-backed firms consolidate services or absorb independent practices, market power can shift quickly, often with limited visibility to patients and communities.
The paper links these trends to a broader antitrust problem. Private equity deals in healthcare are often left unreported, unreviewed, and unregulated, leaving the majority of transactions outside the public and regulatory radar. In practical terms, that means markets can change hands and change shape without the level of scrutiny routinely applied to other mergers or acquisitions that affect competition.
Short-Term Revenue Pressures Can Reshape Care Delivery
Private equity’s operating logic is at the center of the critique. The model is designed to maximize short-term returns, often through debt, asset reconfiguration, and aggressive revenue strategies. In healthcare, those incentives can collide with the long horizon required for stable clinical operations, workforce retention, and sustained community access.
The white paper argues that this mismatch makes private equity fundamentally incompatible with a stable, competitive healthcare system that serves patients and promotes population health. That is a strong claim, but it follows a familiar antitrust pattern: when ownership is concentrated and financial targets are prioritized over service continuity, patients may experience less competition, fewer options, and greater instability in access to care.
For clinicians and health system leaders, the concern is not abstract. Consolidation can alter referral patterns, staffing structures, service lines, and the availability of independent decision-making inside practices and facilities. In a market shaped by private equity, the pressure to generate revenue quickly can affect how care is organized long before any formal quality metric captures the change.
Regulatory Gaps Leave Most Transactions in the Shadows
The paper calls private equity a largely hidden sector of healthcare ownership. Because most deals are not reported or reviewed in a meaningful way, policymakers may not know how quickly control is shifting or how many transactions are clustering within a given market. Without that visibility, antitrust enforcement becomes reactive rather than preventive.
Laura Alexander of the American Antitrust Institute and Richard Scheffler of UC Berkeley say urgent action is needed to understand the effect of private equity on patients and healthcare markets. Their recommendations include changes to antitrust reporting requirements, withdrawal of the Department of Justice guidance on remedies, and study of additional oversight of healthcare mergers by the Department of Health and Human Services.
The policy request is specific because the problem is specific. Existing tools are not capturing the full scope of healthcare ownership changes, and the paper argues that the current framework allows too many transactions to proceed without adequate review of their competitive consequences.
Patient Risk Extends Beyond Ownership Changes
Private equity investment is not portrayed here as a neutral financial event. The paper says the consequences reach patients, competition, and public health. When consolidation accelerates and competition weakens, the downstream effects can include less market restraint, greater concentration of services, and a healthcare environment where patient welfare is subordinated to investor timelines.
Scheffler describes the growth in private equity investment as “astronomical,” and he links that expansion directly to the business priorities embedded in the model. The concern is not just that more healthcare assets are being acquired. It is that the structure of those acquisitions rewards rapid monetization, which can destabilize markets that depend on continuity, trust, and long-term coordination.
The legal and clinical stakes are converging
A healthcare system built around stable competition is supposed to reward better access, better service, and more responsive care. Private equity, as framed in this white paper, can move in the opposite direction by concentrating ownership and narrowing the field of independent actors.
Alexander said the ramifications are still unfolding, but the speed of change leaves little room for delay. Her warning is aimed at the policy window, not at some distant future: the faster private equity transforms healthcare markets, the harder it becomes to unwind the effects after consolidation has already taken hold.
The paper closes with a clear policy demand rather than a speculative one. Oversight, investigation, and a deeper accounting of private equity’s role in healthcare are presented as immediate necessities, not academic luxuries. The unresolved question is not whether private equity matters to healthcare markets; it is how much damage accumulates before regulators intervene with rules that match the scale of the investment wave.